% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Bischof:1030418,
      author       = {Bischof, Gérard N. and Brendel, Matthias and Barthel,
                      Henryk and Theis, Hendrik and Barbe, Michael and
                      Bartenstein, Peter and Claasen, Joseph and Danek, Adrian and
                      Höglinger, Günter and Levin, Johannes and Marek, Ken and
                      Neumaier, Bernd and Palleis, Carla and Patt, Marianne and
                      Rullmann, Michael and Saur, Dorothee and Schroeter, Matthias
                      L. and Seibyl, John and Song, Mengmeng and Stephens, Andrew
                      and Sabri, Osama and Drzezga, Alexander and van Eimeren,
                      Thilo},
      title        = {{I}mproved {T}au {PET} {SUVR} {Q}uantification in
                      4-{R}epeat {T}au {P}henotypes with [18{F}]{PI}-2620},
      journal      = {Journal of nuclear medicine},
      volume       = {65},
      number       = {6},
      issn         = {0097-9058},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {FZJ-2024-05291},
      pages        = {952 - 955},
      year         = {2024},
      abstract     = {We used a new data-driven methodology to identify a set of
                      reference regions that enhanced the quantification of the
                      SUV ratio of the second-generation tau tracer
                      2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c′]dipyridine
                      ([18F]PI-2620) in a group of patients clinically diagnosed
                      with 4-repeat tauopathy, specifically progressive
                      supranuclear palsy or cortical basal syndrome. The study
                      found that SUV ratios calculated using the identified
                      reference regions (i.e., fusiform gyrus and crus-cerebellum)
                      were significantly associated with symptom severity and
                      disease duration. This establishes, for the first time to
                      our knowledge, the suitability of [18F]PI-2620 for tracking
                      disease progression in this 4-repeat disease population.
                      This is an important step toward increased clinical utility,
                      such as patient stratification and monitoring in
                      disease-modifying treatment trials. Additionally, the
                      applied methodology successfully optimized reference regions
                      for automated detection of brain imaging tracers. This
                      approach may also hold value for other brain imaging
                      tracers.},
      cin          = {INM-5 / INM-2},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-5-20090406 / I:(DE-Juel1)INM-2-20090406},
      pnm          = {5253 - Neuroimaging (POF4-525) / 5254 - Neuroscientific
                      Data Analytics and AI (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5253 / G:(DE-HGF)POF4-5254},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {38575191},
      UT           = {WOS:001251294600021},
      doi          = {10.2967/jnumed.123.265930},
      url          = {https://juser.fz-juelich.de/record/1030418},
}